Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2020-02-21 Regulatory Filings
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is very short (537 characters) and appears to be a brief notice or schedule related to an analyst or investor interaction event. It includes details such as date, type of interaction, and location, but contains no financial data, no detailed report content, and no regulatory or filing-specific language. It does not contain any financial statements or substantive analysis. It is not a report itself but rather an announcement or notification related to investor relations. Given the brevity and nature of the content, it best fits the category of Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing that does not fit other categories.
2020-02-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a full transcript of an earnings conference call for Laurus Labs Q3 FY2020, including detailed financial results, business segment performance, management commentary, and Q&A session. It contains specific quarterly and nine-month financial figures, operational updates, and forward-looking statements. The presence of a moderator, management speakers, and investor questions confirms it is a call transcript. There is no indication that this is a brief earnings release or a report publication announcement. Therefore, the document fits the definition of a Call Transcript (CT).
2020-02-10 English
Investor Presentation
Regulatory Filings
2020-02-04 English
Investor Presentation
Regulatory Filings Classification · 100% confidence The document text contains only placeholders for images and no substantive text or financial data. The true document length is only 176 characters, which is extremely short and contains no report content. It does not contain any financial statements, regulatory references, or report titles. Given the lack of content, this is likely a placeholder or an announcement without actual report data. According to the rules, such a short document with no report content should be classified as a Regulatory Filing (RNS) as a fallback category.
2020-01-30 English
Press Release
Regulatory Filings
2020-01-30 English
Financial Result Updates
Regulatory Filings
2020-01-30 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.